Benjamin Derman to Immunotherapy, Adoptive
This is a "connection" page, showing publications Benjamin Derman has written about Immunotherapy, Adoptive.
Connection Strength
1.450
-
Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US. Clin Lymphoma Myeloma Leuk. 2026 Oct; 26(10):e1202-e1210.e8.
Score: 0.186
-
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799.
Score: 0.184
-
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542.
Score: 0.182
-
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Front Immunol. 2025; 16:1558275.
Score: 0.170
-
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025 04; 39(4):816-826.
Score: 0.168
-
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
Score: 0.162
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 08; 25(8):e374-e387.
Score: 0.160
-
Maybe you can't drive this CAR? Blood Adv. 2024 02 27; 8(4):1030-1031.
Score: 0.158
-
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025 Mar; 39(3):543-554.
Score: 0.042
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
Score: 0.038